184 related articles for article (PubMed ID: 35863893)
1. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant
Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C
J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893
[No Abstract] [Full Text] [Related]
2. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
3. Broadening horizons with
Ballal S; Yadav MP; Bal C; Sahoo RK; Tripathi M
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):934-946. PubMed ID: 31707430
[TBL] [Abstract][Full Text] [Related]
4. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
[TBL] [Abstract][Full Text] [Related]
5. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
[TBL] [Abstract][Full Text] [Related]
6. Prediction of
Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
[TBL] [Abstract][Full Text] [Related]
7.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
9. Visual and whole-body quantitative analyses of
Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
[TBL] [Abstract][Full Text] [Related]
10. Long-term prognostic factors for PRRT in neuroendocrine tumors.
Trautwein NF; Schwenck J; Jacoby J; Reischl G; Fiz F; Zender L; Dittmann H; Hinterleitner M; la Fougère C
Front Med (Lausanne); 2023; 10():1169970. PubMed ID: 37359009
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
[TBL] [Abstract][Full Text] [Related]
13. Survival predictors of
Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
[TBL] [Abstract][Full Text] [Related]
15. The efficacy, toxicity and survival of salvage retreatment PRRT with
Sitani K; Parghane R; Talole S; Basu S
Br J Radiol; 2022 Sep; 95(1137):20210896. PubMed ID: 35816545
[TBL] [Abstract][Full Text] [Related]
16. Peptide Receptor Radionuclide Therapy Using
Kalantarhormozi M; Hassanzadeh S; Rekabpour SJ; Ravanbod MR; Jafari E; Amini A; Dadgar H; Mahmoudpour M; Nabipour I; Jokar N; Assadi M
World J Nucl Med; 2022 Sep; 21(3):215-221. PubMed ID: 36060085
[No Abstract] [Full Text] [Related]
17. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
18.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
